MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Amisulpride

CAS No. : 71675-85-9

MCE 国际站：Amisulpride

产品活性：Amisulpride 是一种多巴胺 D₂/D₃ 受体拮抗剂，对于人多巴胺 D₂ 和 D₃ 的 K_i 值分别为 2.8 和 3.2 nM。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：Dopamine Receptor

In Vitro: Amisulpride is an atypical dopamine D₂/D₃ receptor antagonist with K_is of 2.8 and 3.2 nM for human dopamine D₂ and D₃, respectively. Amisulpride (100 nM) inhibits quinpirole-elicited [³H]thymidine incorporation with an IC₅₀ value of 22±3 nM (n=3). Amisulpride slightly but significantly increases [³H]dopamine release from slices of the rat striatum (S₂/S₁=0.88±0.04 under control conditions, n=6; 1.04±0.08 in the presence of 100 nM Amisulpride,n=4; P<0.05) and opposes the inhibitory effects of 7-OH-DPAT in both brain areas.

In Vivo: Only the highest dose of Amisulpride (100 mg/kg) significantly reduces dopamine levels in the striatum or limbic system. Amisulpride significantly increases the synthesis of dopamine in the rat striatum and limbic system at doses of 20 and 100 mg/kg. Amisulpride (0.5 to 75 mg/kg) fails to provoke an additional increase in dopa accumulation in the striatum but slightly accelerates, at 75 mg/kg, dopamine synthesis in the limbic system. In comparison with vehicle-treated controls, Amisulpride (10 mg/kg) increases extracellular dopamine levels. The administration of Amisulpride (0.5 to 15 mg/kg s.c.) provokes a time- and dose-dependent increase in the stimulation-evoked dopamine release. Amisulpride decreases striatal ACh levels significantly at 30 and 100 mg/kg (87.5% and 56.3% of control levels, respectively). In both acute study, Amisulpride (70 mg/kg, p.o.) significantly increases the duration of swimming behavior [F(3,28)=45.90, p<0.01].

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Neurodegenerative Disease-related Compound Library  |  FDA-Approved Anticancer Drug Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Perphenazine-d₈ dihydrochloride  |  Haloperidol  |  PG01037 dihydrochloride  |  Zotepine  |  Paliperidone-d₄  |  Nuciferine  |  Preclamol hydrochloride  |  Sonepiprazole  |  Ziprasidone hydrochloride monohydrate  |  WAY-100635 Maleate  |  CY 208-243  |  Paliperidone palmitate  |  Raclopride tartrate  |  Trifluoperazine dihydrochloride  |  Paliperidone  |  Sulpiride  |  Ecopipam  |  Clebopride malate  |  PNU-96415E  |  Fluoroclebopride  |  L-DOPA-d₆  |  FAUC 213  |  Raclopride-d₅ hydrochloride  |  Alizapride  |  Tiapride  |  MLS1547  |  Dopamine-d₅ hydrochloride

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。